A downregulation of Oct-4 (57%), Sox2 (47%) and Nanog (17%) in mCRPC/NEPC (PC-3M), and downregulation of Oct-4 (28%), Sox2 (61%), and Nanog (35%) in taxane-resistant mCRPC/NEPC (DUTXR) prostate cancer cell line model was observed after combination treatment. This evidence concerns the gene SOX2 and prostate carcinoma.